Mineralys Therapeutics (MLYS) Insider Karydas Buys $36K of Stock

Daphne Karydas Grows Mineralys Therapeutics Holding

Mineralys Therapeutics, Inc. (NasdaqGS: MLYS) saw insider Daphne Karydas pick up 3,000 shares of the biotech company on June 17, 2026. The purchase was executed at a price of $12.02 per share, bringing the total value of the transaction to $36,060. This transaction fits into a wider pattern of recent insider moves across the company, adding to prior coverage of executive trades at the firm.

MLYS Stock Performance and Trading Levels

The company's shares recently traded at $25.13 on the market. That places the stock between its 52-week low of $22.30 and its 52-week high of $47.65. The shares have been hovering near the 50-day moving average of $27.12 and below the 200-day moving average of $28.95. Market capitalisation for the biopharmaceutical firm stands at roughly $2.50 billion.

Recent Insider Transactions at Mineralys Therapeutics

Executive activity at the firm has been busy through the middle of the year. On June 26, 2026, Chief Commercial Officer Eric Warren bought 104,124 shares at a price of $13.24 for a total of $1,378,601.76, while also reporting a disposition of an equal share count. Chief Executive Officer Jon Congleton sold 75,000 shares on June 30, 2026, in a planned transaction valued at $1,960,462.50 at an average price of $26.14. Chief Medical Officer Rodman David Malcom bought 4,584 shares on June 17, 2026, at an average price of $14.36 worth $65,818.45, alongside a planned sale of 4,584 shares at $25.00 on the same date. Daphne Karydas also executed a planned sale of 3,000 shares at $25.00 valued at $75,000 on June 17, 2026, alongside the acquisition noted above.

Analysts Set New Price Targets

Wall Street firms maintain an active outlook on the biotechnology firm. On October 12, 2026, UBS initiated coverage on the stock with a Neutral rating and a $29.00 price target. On the same day, HC Wainwright & Co. reiterated its Buy rating on MLYS with a price target of $56.00. Across the board, the company carries a consensus mean price target of $48.50 based on eight analyst opinions, with high and low targets set at $56.00 and $30.00 respectively.

Inside the Pipeline at Mineralys Therapeutics

Mineralys Therapeutics is a clinical-stage biopharmaceutical company based in Radnor, Pennsylvania. The firm focuses on developing targeted medicines for diseases driven by dysregulated aldosterone, including conditions like hypertension, chronic kidney disease, and obstructive sleep apnea. Its lead candidate is an orally administered aldosterone synthase inhibitor called lorundrostat.

What to Watch Next for MLYS

Investors tracking the healthcare firm will look ahead to its next scheduled earnings report, which is expected on November 10, 2026. Further Form 4 filings with the SEC will show whether executives continue adjusting their shareholdings as clinical programs advance.